Kaomi ma aneʻi e hōʻike i kāu mau hae ma kēia ʻaoʻao a uku wale no ka holomua

Nuhou Uea

ʻApono ʻia ka Lapaʻau ʻana no ka Myeloma Nui i hoʻihoʻi hou ʻia a me Refractory

i kakauia ma hoʻoponopono

Ma Australia ma kahi o 2,400 poʻe i loaʻa i kēlā me kēia makahiki me ka myeloma lehulehu (MM), a ma kahi o 20,000 mau maʻi e noho nei me MM i kēlā me kēia manawa. ʻO ka mea pōʻino, ʻoi aku ma mua o 1000 mau maʻi e make i kēia ʻano o ka maʻi kanesa koko i kēlā me kēia makahiki a no laila pono nā koho lapaʻau hou e like me XPOVIO®.              

Ua hoʻolaha ʻo Antengene Corporation Limited i kēia lā ua hoʻopaʻa inoa ʻo Therapeutic Goods Administration (TGA) o ka Australian Government Department of Health iā XPOVIO® (selinexor) no nā hōʻailona ʻelua: (1) I hui pū ʻia me ka bortezomib a me ka dexamethasone (XBd) no ka mālama ʻana i nā maʻi makua me ka myeloma lehulehu (MM) i loaʻa ma kahi o hoʻokahi lāʻau lapaʻau mua a (2) i hui pū ʻia me ka dexamethasone (Xd) no ka mālama ʻana i nā poʻe maʻi makua me ka myeloma lehulehu (R/R MM) refractory i loaʻa ma kahi o ʻekolu. nā lāʻau lapaʻau mua a ʻaʻole hoʻi ka maʻi i ka liʻiliʻi loa i hoʻokahi mea paʻa proteasome (PI), ma kahi liʻiliʻi hoʻokahi huahana lāʻau immunomodulatory (IMiD), a me kahi anti-CD38 monoclonal antibody (mAb).

ʻO XPOVIO® ka SINE mua a ʻo ia wale nō i ʻāpono ʻia e ka TGA e kōkua i ka hoʻihoʻi ʻana i nā ala hoʻopaʻa tumora ponoʻī o ke kino.

Ua ʻōlelo ʻo Polofesa Hang Quach, Haematologist ma St Vincent's Hospital, Melbourne, "Ua pōmaikaʻi wau e lilo i hoʻokahi o nā mea noiʻi ma ka noiʻi lapaʻau ʻo BOSTON a ua kākau pū ʻia ma kekahi mau pepa ma ka XBd regimen. ʻAʻole kānalua kēia regimen triplet i koʻu noʻonoʻo ma waena o nā lāʻau lapaʻau maikaʻi loa no ka hoʻihoʻi mua ʻana i ke au o ka lenalidomide refractoriness. Ma nā hōʻiliʻili subset, ʻoi aku ka maikaʻi o kēia regimen triplet me ka nānā ʻole i ka makahiki, nā maʻi palupalu a i ʻole nā ​​​​maʻi palupalu a maikaʻi i nā poʻe maʻi me ka haʻahaʻa o ka creatinine clearance. ʻO ka mea nui, ʻoi aku ka maikaʻi o ka hui ʻana o XBd i nā maʻi me nā cytogenetics kiʻekiʻe.

Ua ʻōlelo hou ʻo Polofesa Hang Quach "Ke manaʻoʻiʻo nei au ʻo nā lālani mua ʻekolu o ka lāʻau lapaʻau no MM ka mea nui loa i ke kuhikuhi ʻana i ke ola holoʻokoʻa o ka mea maʻi no ka mea ʻo ka hapa nui o nā mea maʻi me MM i ka honua maoli ʻaʻole e ola e ʻike i ka lālani ʻehā o ka lāʻau lapaʻau a i ʻole. ma o aku. Eia kekahi, loaʻa ka pōmaikaʻi lapaʻau nui loa i ka wā e hoʻohana ʻia ai kahi lapaʻau kūpono i ka hoʻihoʻi ʻana o ka laina mua. No laila he mea nui ka hāʻawi ʻia ʻana o ke kauka lapaʻau i kahi koho kūpono i kēlā "hoʻokahi a ʻekolu laina mua" i hiki ke hoʻohana ʻia ka regimen maikaʻi loa e pili ana i ka ʻike pilikino o ka mea maʻi. ʻO ka nele o nā koho kūpono no nā poʻe maʻi lenalidomide-refractory i ka hoʻi hou ʻana o ka laina mua o MM kahi wahi o ka pono ʻole ma Australia. ʻO ka loaʻa ʻana o XPOVIO®, bortezomib a me dexamethasone ma ke ʻano he koho ma kēia wahi e hoʻoponopono i kēia pono ʻole.

"Ma Australia, hoʻokahi wahi koʻikoʻi o ka pono ʻole o ka poʻe maʻi me ka myeloma ka nele o nā lāʻau lapaʻau kūpono no nā poʻe maʻi he triple-class refractory, ʻo ia ka refractory i ka proteasome inhibitor, immunomodulatory drug a me kahi anti-CD38 monoclonal antibody. ʻO ka pōmaikaʻi o XPOVIO® ʻo ia ka lāʻau lapaʻau waha me kahi ʻano hana hou o ka hana i kūpono ia no nā maʻi refractory papa triple. Hiki i ka XPOVIO® ke hoʻoulu i nā pane a hoʻolōʻihi i ke ola ma ke ʻano koʻikoʻi," wahi a Professor Andrew Spencer, Haematologist, Alfred Hospital, Melbourne.

Ua ʻōlelo ʻo Hayley Beer, Interim Co-CEO o Myeloma Australia, "He mea nui ka loaʻa ʻana o kahi koho lapaʻau ʻē aʻe no ka poʻe e noho ana me ka myeloma lehulehu, ma nā laina mua a ma hope o ka lāʻau lapaʻau. ʻO XPOVIO® kahi papa lāʻau hou me kahi ʻano hana kūʻokoʻa, no laila hiki i nā mea maʻi ke hoʻāʻo i kahi hui hou me ka ʻole e hana hou i kahi papa lāʻau i hoʻohana mua ʻia.

"He mea nui kēia no Antengene a no nā mea maʻi MM ma Australia. Ua hauʻoli nui mākou i ka hoʻolaha ʻana iā XPOVIO® a lawe mai i nā kauka a me nā maʻi o Australia i kahi hou hou i kā lākou mau regimens no ka mālama ʻana iā R/R MM. E like me kā mākou huahana mua e hoʻopaʻa inoa ʻia ma Australia, ʻo ia hoʻi ka hōʻailona o ka ulu ʻana o Antengene ma Australia i kahi hui biopharmaceutical me ka hoʻokō e hoʻomau i ka hoʻomohala ʻana a me ke kālepa ʻana o nā lāʻau lapaʻau hoʻololi no ka maʻi kanesa a me nā maʻi hoʻoweliweli ʻē aʻe ma Australia, "wahi a Thomas Karalis, CVP Asia Pacific o Antengene.

"ʻO ke ʻano o nā ʻae i hāʻawi ʻia iā XPOVIO® ma Kina, South Korea, Singapore a i kēia manawa ʻo Australia i nā mahina ʻeono i hala aku nei ua hōʻike i ka hiki ke hoʻōla nui ʻia ka lāʻau. Ma Australia, aia ma kahi o 2,400 mau maʻi maʻi o MM i kēlā me kēia makahiki, no laila e hōʻike ana i kahi koi koʻikoʻi koʻikoʻi i ka mālama ʻana iā MM, "wahi a Jay Mei, ka mea hoʻokumu o Antengene, Luna Hoʻokele a me Luna Nui. "ʻO kēia ʻae ʻia e ka TGA ke hoʻololi nei i nā maʻi ma Australia i loaʻa i ka maʻi MM. Ua paʻa mākou i ka lawe ʻana i nā lāʻau lapaʻau hou a me nā lāʻau lapaʻau i nā poʻe maʻi me ka maʻi kanesa a i ʻole nā ​​​​maʻi weliweli ʻē aʻe ma ka ʻāina ʻo Asia Pacific a puni ka honua. I kēia manawa, mākaukau maikaʻi kā mākou hui pāʻoihana e hoʻonui i ke komo ʻana o nā poʻe maʻi i kēia lāʻau lapaʻau hou, e kūkulu ana ma luna o kā mākou ʻike kalepa me XPOVIO® hoʻokuʻu ʻia ma Kina, Singapore a me South Korea.

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

Kaʻana like i...